Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotech Startup Investors in Ireland

Last updated: Jul 2024 A list of 50 angel investors and VC funds that invest in Biotech startups based in Ireland. We rank investors based on the number of investments they made in Biotech companies from Ireland. We update this investor list every month.

Top 50 Biotech Startup Investors in Ireland

Investor	Biotech Ireland investments
Enterprise Ireland	30
SOSV	19
Western Development Commission	11
Kernel Capital	9
Irrus Investments	6
AIB Seed Capital Fund	6
Fountain Healthcare Partners	6
Seroba Life Sciences	5
European Investment Bank	4
Atlantic Bridge	4
Act Venture Capital	3
Atlantic Bridge University Fund	3
HBAN Medtech Syndicate	3
The Yield Lab Europe	3
Boole Investment Syndicate	2
Infinity Capital	2
Enterprise Equity	2
SVG Ventures	2
HealthCap	2
Furthr VC	2
SVG Ventures	2
Lightstone Ventures	2
Ascent Capital	1
Silicon Valley Bank	1
Clay Capital	1
Eoghan Quigley	1
The Yield Lab	1
Bpifrance	1
Covidien	1
Street Capital	1
Novartis Venture Fund	1
Carbery Group	1
Kreos Capital	1
HBM-MedFocus	1
Cambridge Innovation Capital	1
Ali Partovi	1
Cultivian Sandbox Ventures	1
Medicxi	1
Apicap	1
The Foundry	1
Earlybird Venture Capital	1
Elkstone Capital Partners	1
EarlyBird	1
Carragh Holdings	1
Medtech Syndicate Nominee	1
Wellcome Trust	1
Tekla Capital Management	1
EQT life science	1
KBI Biopharma	1
Third Swedish National Pension Fund	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Xocean — Using unmanned surface vessels (USVs), XOCEAN offers turnkey data collection services to Surveyors, Companies and Agencies.
Lua Health — We believe the future of well-being is in prevention and early detection. Getting the right help, at the right time.
MarketSizer — MarketSizer offers subscription-based competitive intelligence and market insights for SaaS vendors who want to strategically grow their business.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
OncoPrecision — We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity and Resistance Test, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access toPrecision Oncology and improve cancer patients' lives.
Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators

Supporting communities to grow, investing in businesses to scale and planning for the future of the western region.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Funding Round, Series A
Ireland, United States

Portfolio highlights

FeelTect — Connected health technology for disruptive improvements to wound care
CitySwift — CitySwift is a data-driven scheduling and planning technology for urban bus networks. It uses artificial intelligence and machine learning to predict journey times and passenger demand, making routes more efficient. Schedulers can create optimized timetables that take into account traffic, events, and hundreds of other external factors, ensuringon-time performance and increased passenger satisfaction.CitySwift was established in 2016 and is operating in Galway, Ireland.
Amara Therapeutics — Amara Therapeutics is passionate about empowering women and men to take control of their pelvic health. Amara Therapeutics use evidence based medicine and behavioural interventions supported by Amara Therapeutics platform of technologies to provide safe, convenient and non-invasive care pathways. At Amara Therapeutics mission is to fix the carepathway for pelvic health patients, connecting healthcare providers, patients and peers through our platform.

Kernel Capital is the independent manager of The Bank of Ireland Kernel Capital Venture Funds, one of the largest and most active sources of equity finance on the island of Ireland. Kernel leverage their extensive network to enable their portfolio companies recruit the highest caliber people, to break into new international markets and to generaterevenues of scale. It is the only investment firm with venture capital Funds dedicated to both jurisdictions on the Island. Kernel have raised over €210M from investors which including their strategic partner Bank of Ireland, Invest NI, Enterprise Ireland, Galway University Foundation, The University of Limerick Foundation, The New York State Common Retirement Fund and undisclosed Family Offices. Consistently delivering strong financial returns for their investors Kernel have led more than 20 substantial trade sales to NASDAQ, NYSE, and LSE listed corporations.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
Ireland, United Kingdom, France

Portfolio highlights

Pretto — Pretto is the only truly transparent online real estate price comparator.Pretto accompanies you until the signing of your loan, free of charge and without commitment.
Pilot Photonics — Welcome to Pilot Photonics, a laser product development company in Dublin, Ireland. We provide optical frequency combs and tunable lasers.
Causeway Sensors — The Affinity, is a compact, bench-top Biosensor providing accurate real-time analysis at an accessible price. The Affinity biosensor and accompanying Access Chip incorporate the latest advancements in Nanotechnology, providing the biochemistry researcher the perfect platform to explore the complex world of biomolecular interactions.

Irrus Investments is the leading Irish business angel network with international connections. Fueling Irish innovation in medical devices, software, hardware, digital healthcare and life sciences.

Investment focus

Medical Device, Biotechnology, Health Care
Seed, Funding Round, Series A
Ireland, Sweden, United States

Portfolio highlights

FeelTect — Connected health technology for disruptive improvements to wound care
Bluedrop Medical — Evidence shows regular inspection of the feet can greatly reduce the risk of developing a diabetic foot ulcer (DFU).
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012.The Fund has a total of â‚¬30m under managementwith AIB and Enterprise Ireland both committing â‚¬15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success.The Fund managers are empowered to make seed investments of up to approximately â‚¬500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies.The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise.Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of â‚¬250,000 from the fund within the city and county of Dublin.Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed â‚¬250,000.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United States, Jersey

Portfolio highlights

NewsWhip — The only real-time media monitoring platform that predicts the stories and topics that will matter in the hours ahead.
Offr — Offr is the new way to buy and sell property, quickly and transparently.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
Ireland, United States, France

Portfolio highlights

MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
Mainstay Medical — Mainstay Medical is improving quality of life for patients with chronic low back pain through innovative restorative treatment medical device solutions.
Ermium Therapeutics — Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.

Seroba is a leading European life sciences venture capital firm focused on value creation through backing winning innovations in biotech and medtech.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Ireland, United States, United Kingdom

Portfolio highlights

Shorla Pharma — Shorla Pharma is an Irish specialty pharmaceutical company. It is growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Artica Therapeutics — Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food.

European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union.The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds;equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds.The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises.EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors.European Investment Bank was founded in 1958 and is based in Luxembourg.

Investment focus

Biotechnology, Health Care, Software
Debt Financing, Post-IPO Debt, Funding Round
France, Germany, The Netherlands

Portfolio highlights

Rohlik — Rohlik is an innovative grocery delivery startup that offers a 90-minute same-day delivery service. Since its inception, Rohlik has been growing and is on track to EUR 300 mil. revenues in 2020. Rohlík was founded in 2014 by Marek Sacha and Tomas Cupr and is headquartered in Karlín, Hlavni mesto Praha, Czech Republic.
Eldrive — The largest charging point operator in Eastern Europe | Our network is expanding rapidly yet our focus is fixed on renewables, for a greener future. We provide AC & DC charging across Bulgaria, Romania and Lithuania.
ABN AMRO Bank — Als bank leggen wij de focus op inclusiviteit, duurzaamheid, sociaal ondernemen, innovatie, dagelijkse bankzaken en meer.

Atlantic Bridge is a Growth Equity Firm with a Cross Border Value Add strategy. We invest in deep technology companies in Europe and the US. Our team is made up of successful entrepreneurs and senior technology industry executives and we invest in strong ambitious entrepreneurs and management teams that have the passion and drive to scale up andexploit major growth opportunities. We help our portfolio companies expand and grow internationally through our global platform with our team and offices in London, Dublin, Munich, Paris and Palo Alto.Atlantic Bridge brings together a unique team of technology entrepreneurs, experienced managers, finance professionals, and investment experts. The team contains a wealth of international business experience across Europe, the UK and the US. They have worked together in various capacities for the last 30 years, bringing a true partnership approach to their firm and their investments. Its investors include the founders, leading institutional investors, and private investors with a track record of investment in successful technology companies.Atlantic Bridge has developed a unique and differentiated strategy that focuses on specific technology themes and the implementation of the “Atlantic Bridge Model” for scaling companies internationally. The “Bridge Model” accelerates the scale-up of technology companies in Europe and the US. This approach is highly differentiated and has delivered strong performance results to date.

Investment focus

Software, Information Technology, Artificial Intelligence
Series A, Series B, Funding Round
United States, Ireland, United Kingdom

Portfolio highlights

Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
Vertigenius — Vertigenius designs and deploys customized exercises using an easy-to-use clinician portal and even uses a Vertigenius head sensor to consult and manage patients with dizziness and imbalance.
Cambridge Mechatronics — Cambridge Mechatronics (CML) is a high technology design and engineering company based in Cambridge, UK. We specialise in pioneering and developing cutting-edge mechatronic platform technology from concept to mass production. We achieve this through technology licensing or partnerships with global manufacturing corporations. Our intellectualproperty portfolio consists of over 100 granted patents that we can exploit.

Technology-focused, investing capital and expertise to fuel growth in the most promising ideas and companies. Raised c.€600m across multiple funds and invest from seed to growth.We look for companies with potentially cutting-edge, category-defining businesses in markets including application software, IT infrastructure, communications, Internetand mobile. We help founders create and scale businesses globally. We work as a small team with diverse strengths accessing a community of over 200 founders. The teams and companies we back scale their investor base as they scale their business execution and ambition. We work closely with them in this process. Over the past 25 years have built a broad network of US and European investors and founders that share our vision and approach.Act is based in Dublin, Ireland.Our most recent funds are supported by the European Investment Fund.

Investment focus

Software, Information Technology, SaaS
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

GridBeyond — Endeco's Energy ManagementSystem (EMS) provides wirelessenergy management and controlsystems for retail, commercial andindustrial users. Applications includebuilding control, refrigeration control,demand management, priceresponse, energy efficiency, anddemand response. Our automatedwireless systems seamlesslyintegrate intoyour existingoperations and/or BuildingManagement System (BMS) withoutany training of retail staff required.
CitySwift — CitySwift is a data-driven scheduling and planning technology for urban bus networks. It uses artificial intelligence and machine learning to predict journey times and passenger demand, making routes more efficient. Schedulers can create optimized timetables that take into account traffic, events, and hundreds of other external factors, ensuringon-time performance and increased passenger satisfaction.CitySwift was established in 2016 and is operating in Galway, Ireland.
Mavarick AI — Mavarick helps manufacturers to achieve sustainability breakthroughs with AI-Driven Carbon Reporting & Management across their operations & entire supply chain

We invest in entrepreneurs with the ambition to create world-class companies of scale.

Investment focus

Medical Device, Health Care, Big Data
Seed, Series A, Funding Round
Ireland, United States

Portfolio highlights

CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
ProVerum Medical — ProVerum Medical is an early stage medical device startup for the treatment of Benign Prostatic Hyperplasia (BPH).
Tympany Medical — Tympany Medical is a Needs-driven, Innovative MedTech StartUp based in the West of Ireland

HBAN Medtech Syndicate

Investment focus

Medical Device, Medical, Health Care
Seed, Funding Round, Series B
Ireland

Portfolio highlights

FeelTect — Connected health technology for disruptive improvements to wound care
Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

The Yield Lab Europe is a €50m early stage Agrifood and Ag Tech fund which comprises an accelerator and a larger follow-on fund, investing in high tech companies with the potential to significant disrupt and improve our current systems of global food production, and to improve the environmental sustainability of the industry. The main fund invests€1m each into 10-12 companies over several follow on rounds, with the strongest accelerator companies expected to progress to the main fund. The Yield Lab Europe is also part of a global network of Agrifood Tech funds, with global headquarters in St Louis USA, and sister funds in LATAM and Singapore.

Investment focus

AgTech, Agriculture, Biotechnology
Seed, Series A, Funding Round
Ireland, France, United Kingdom

Portfolio highlights

Oligofeed — We developed a supplement boosting bee immunity. Our non-toxic bee-feeding product reduces bee mortality and improves the production of the hives.
Marama Labs — Marama Labs provides an integrated chemical analysis platform that empowers customers to optimize their production processes and match their products and brands to customer needs, with ease.
Micron AgriTech — Micron Agritech, driving the future of sustainable animal health. Run a FEC worm or fluke test with your phone and get results in minutes.

Boole Investment Syndicate invests in new technology start-up's with scalability.

Investment focus

Medical Device, SaaS, EdTech
Seed, Funding Round
Ireland, United States

Portfolio highlights

FeelTect — Connected health technology for disruptive improvements to wound care
Hooke Bio — Hooke Bio is a new Pharmaceutical company operating in the preclinical to early stages of drug discovery. It draws its strength from the close co-operation it has between its biologists and engineers. The engineers design, patent and test new microfluidic technology: the scientists apply the technology to finding new therapeutics.
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

Infinity Capital are hypothesis-driven investors - constantly calibrating ideas through a Silicon Valley/technology network that they've been building for over two decades. Their extensive technology and operating backgrounds, combined with over a dozen years each of successful startup investing, have been essential in buildingcredibility and a reputation that resonates with entrepreneurs.

Investment focus

Semiconductor, E-Commerce, Electronics
Series B, Funding Round, Series D
United States, Ireland, Canada

Portfolio highlights

AltraTech — Next Generation Molecular Detection Discover Altratech Next Generation Molecular Detection Discover Altratech At Altratech, our mission is to enable next generation molecular detection.
BioSapien — BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects. The applications for this technology are currently under investigation for pancreatic cancer and lung cancer. The intended pipeline ofindications is expected to expand into other cancers such as colorectal, breast, and stomach cancers. BioSapien's 3D-printed MediChip delivers FDA-approved toxic high-dose systemic therapies in a localized slow-release biodegradable mesh which is able to target tissues while improving patients' quality of care and life.
Core Starters — Core Starters services startups and investors through blockchain-based decentralized services to solve real problems.

Enterprise Equity (or EEVC) is an excellent for providing capital to early stage and expanding business throughout Ireland.

Investment focus

Software, Information Technology, Medical Device
Funding Round, Seed, Series B
Ireland, United States, United Kingdom

Portfolio highlights

Phorest — Join 8000+ spas, barbers, hair, beauty and nail salon owners using the #1 management, scheduling, POS and appointment booking system. Try Phorest now!
SurgaColl — SurgaColl Technologies is a medical device company developing novel tissue regeneration products for the surgical treatment of diseases of the bone, cartilage and other human tissue. Based on technology developed at the Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland (RCSI), headed by Professor Fergal O’Brien,the company aims to become a leader in the field of regenerative medical devices.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

We work with leading corporations, startups, universities, and growers to solve the biggest challenges facing the agtech and foodtech industries.

Investment focus

AgTech, Agriculture, Farming
Pre-Seed, Seed, Funding Round
United States, Canada, Ireland

Portfolio highlights

FarmWise — FarmWise provides technology-based services that allow farmers to streamline farm operations and increase food production efficiency.
Napigen — We are the genome editing company specialized for mitochondrial engineering. We address unmet needs of future food supplies by creating hybrid crop plants to boost their yields to an unprecedented level. The company’s technology creates robust male sterile lines that are ideal over conventional lines because of their stability and elitebackgrounds. This allows the production of non-GM hybrid seeds in crop plants that are currently mostly non-hybrid such as wheat. Our technology solution is expected to fulfill the highest level of public acceptance and aspiration.
Iamus Technologies — Iamus Technologies Limited is an Artificial Intelligence & Robotics company based in Ireland that has developed poultry specific robotic technology that empowers poultry farmers to make better and safer production decisions. Over the last 2 years we have been working globally with poultry processors in identifying KPIs that our robots cancontinuously gather on the ground in poultry sheds and feedback instantly to both producer and the relevant personnel back at the processing plant. Results to date are impressive with automatic and accurate data recovery from the birds on every part of the floor and analysis with real-time intervention now possible. These factors are key in addressing the growing demands of modern, intensive broiler production with the Iamus robot & platform meeting these requirements.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Sweden, France

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.

Furthr VC invests in transformative tech. Furthr Venture Capital invests in scalable, early-stage companies. We help Ireland's next generation of technology.

Investment focus

Medical, Medical Device, Health Care
Seed, Funding Round, Pre-Seed
Ireland

Portfolio highlights

GREYSCOUT — Need brand protection? Our best brand protection software monitors & removes unauthorized listings, helping businesses fight online counterfeiting.
Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

We work with leading corporations, startups, universities, and growers to solve the biggest challenges facing the agtech and foodtech industries.

Investment focus

AgTech, Agriculture, Farming
Pre-Seed, Seed, Funding Round
United States, Canada, Ireland

Portfolio highlights

scoutlabs — We're building the world's densest digital trap network to accurately gauge insect pest pressure. This helps millions of farmers in precisely combating crop-eating insects, accelerating a transition to more sustainable methods. Good for the farmer, the environment and for our food security
Cynomys — Soluzioni IOT di monitoraggio ambientale per allevamenti e aziende
Verdi Expeditions — Verdi is building the world's first truly scalable platform for farm automation. We work with the world's largest food brands to grow better and more sustainable crops.

Lightstone Ventures is a global venture capital firm that invests in personalized medicines and targeted therapeutics. Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing inbreakthrough life science companies during a time of unique opportunity in space.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Ireland, Singapore

Portfolio highlights

Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
Reprieve Cardiovascular — Reprieve Cardiovascular is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients.

Ascent Capital is a leading India-focused independent private equity firm. They are one of the most experienced teams on ground with over 150+ years of collective experience in Indian capital markets. Over the past 15 years they have helped over 55 entrepreneurial teams build leading businesses across diverse sectors such as Technology, Ecommerce,Healthcare, Financial Services, Consumer Brands, Infrastructure, etc.

Investment focus

Software, Financial, Gaming
Funding Round, Series C, Series B
India, United States, Ireland

Portfolio highlights

Haber — We provide automation solutions for the Pulp and Paper Industry. We have expertise in process automation for chemical dosing. Our solutions are scalable to food and beverage, institutions with HVAC applications as well as metals and mining industries.
EnKash — Enkash is now Asia's 1st and Smartest Spend Management Platform that offer services like Account Payable, Accounts Receivable, Expense Management & many more.
MyGlamm — MyGlamm is a direct-to-consumer beauty brand that offers an online beauty products marketplace with international spa and salon products. The company uses a combination of technology, content, and social media to allow consumers to not only discover its products but also create rich, personalized, content and tutorial.MyGlamm was founded in 2015and is headquartered in Mumbai, Maharashtra.

Silicon Valley Bank is the financial partner of the innovation economy; helping individuals and investors in the innovation ecosystem achieve extraordinary outcomes.

Investment focus

Software, Health Care, Biotechnology
Debt Financing, Series B, Series A
United States, United Kingdom, Canada

Portfolio highlights

Denim — Denim is an all-in-one financial enablement platform for the logistics industry. We work with brokerages to offer freight factoring and back office automation.
Harness — Harness is a self-service CI/CD platform that allows engineers and DevOps to build, test, deploy, and verify software, on-demand.
Parafin — Parafin provides you with an end-to-end solution to offer one-click financing to your sellers.

VisVires New Protein is a pioneering investor focused on solving the persistent challenges of our food and feed system.

Investment focus

Food and Beverage, Biotechnology, Health Care
Series A, Series B, Funding Round
France, Israel, Germany

Portfolio highlights

Cook-e — Cook-e's robotic kitchen automatically prepares warm dishes such as bowls, pastas, woks, from fresh ingredients. Recipes can be entered in the software controlling the robot. The robot can cook up to 100 dishes/hour.
Infinite Roots — Mushlabs is a biotech company using fermentation to create the next generation of sustainable foods from the roots of mushrooms.
TOOPI Organics — TOOPI Organics is specializing in using human urine for agriculture and industry

Eoghan Quigley

Investment focus

Medical, Biopharma, Health Care
Seed
Ireland

Portfolio highlights

Beyondbmi — Beyondbmi is an expert led medical approach to weight loss. We provide a convenient and scientific telehealth program designed to help your reach your health goals.

The Yield Lab invests in AgriFood Tech companies with technologies focused on crops, animal health, digital agriculture, logistics, and food ingredients. Initial investments range from $100,000 – $1.5M.

Investment focus

Agriculture, AgTech, Biotechnology
Seed, Series A, Convertible Note
United States, Argentina, Brazil

Portfolio highlights

Seedz — Seedz - Home - Produtores
Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
NanobOx — We use a low-voltage electric field to generate nanobubbles directly in water; significantly reducing the energy cost compared to conventional methods.

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
France, United States, Switzerland

Portfolio highlights

RSight — RSight offers each customer, candidate, and partner with a one-of-a-kind and best-in-class recruitment, onboarding, and working experience. The company, above and beyond the current industry possibilities in providing enhanced service to recruiting organizations and individuals. The company is elevating the recruitment experience and interaction byproviding recruitment experience for each client, candidate, and partner.
Skynopy — Connecting satellites. As a service
C12 Quantum Electronics — C12 Quantum Electronics develop reliable quantum processors with carbon nanotubes. Its unique technology reduces drastically the error rate, making the platform a prime candidate for noisy intermediate-scale quantum applications. The Paris, Ile-de-France, France-based company was formed in 2019 by Pierre and Matthieu Desjardins.

Covidien plc engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings. Segments The company operates its businesses through four segments: Medical Devices includes the development, manufacture and sale of endomechanical instruments, soft tissue repair products, energy devices, oximetry andmonitoring products, airway and ventilation products, vascular devices, SharpSafety products, clinical care products and other medical device products; Imaging Solutions includes the development, manufacture and marketing of radiopharmaceuticals and contrast products; Pharmaceutical Products includes the development, manufacture and distribution of dosage pharmaceuticals and active pharmaceutical ingredients; and Medical Supplies includes the development, manufacture and sale of nursing care products, medical surgical products and original equipment manufacturer products (OEM). The Medical Device segment develops, manufactures and sells an array of products which the company categorizes in the following product groups: - Endomechanical Instrumentsâ includes its laparoscopic instruments and surgical staplers. - Soft Tissue Repair Productsâ includes its sutures, mesh and biosurgery products. - Energy Devicesâ includes its vessel sealing, electrosurgical and ablation products and related capital equipment. Oximetry and Monitoring Productsâ includes its sensors, monitors and temperature management products. Airway and Ventilation Productsâ€”includes its airway, ventilator, breathing systems, sleep and inhalation therapy products. Vascular Devicesâ ”includes its compression and vascular therapy products. SharpSafety Productsâ includes its needles, syringes and sharps disposable products. Clinical Care Productsâ includes its urology, enteral feeding and other advanced woundcare products.

Investment focus

Health Care, Biotechnology, Science/Engineering
Series A
Ireland

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Street Capital Financial Corporation is a Canadian wholesale lending company. As a wholesale lender, Street Capital doesnâ€™t have an expensive branch network and as such can pass those savings to the consumer. Street Capital prides itself on offering consumers competitive products and interest rates with an exceptional level of service.Havingapproved lender status with Canada Mortgage and Housing Corporation (CMHC) Street Capital is able to offer a broad spectrum of residential mortgage financing products to the consumer. Also, since weâ€™re primarily focused on the mortgage broker origination channel, youâ€™re assured that your mortgage will fit your needs comfortably.By continually working to develop innovative lending solutions and working in partnership with your local mortgage brokers, Street Capital is proud to help more Canadians realize their dreams of home ownership and enhancement.

Investment focus

Medical, Automotive, Biotechnology
Seed, Funding Round
Ireland, United States

Portfolio highlights

Biosensia — Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing. RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications. Its componentchip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
Drive Time Metrics — Drive Time Metrics is developing innovative new revenue streams from connected car data, and helping automotive OEMs monetize their connected vehicle platforms.

Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program.We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. SectorsNew therapeutics & platformsMedical devices/implantsDiagnostics/biomarkersDrug delivery/biopolymersGeographyUSA/CanadaEuropeSwitzerlandAsia/Pacific

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.

Pioneering research and expertise in action. Through innovati drive new product innovation that creates value for our.

Investment focus

Life Science, Biotechnology, Marine Technology
Seed
Ireland

Portfolio highlights

Pure Ocean Algae — Pure Ocean Algae is a biotechnology company that integrates value chains from macro-algae and other marine resources. The company has over the winter of 2019/20 deployed its first trial lines of Palmaria palmata to sea, with initial results being extremely positive. It has also taken primary research in tank-based vegetative production andsucceeded in developing a pilot commercial plant that can produce commercial volumes of Palmaria palmata, at levels approaching 100% per week.

Kreos Capital is Europe's largest and leading provider of growth debt to high-growth companies with revenues up to €150 million. Since 1998, as the pioneer growth debt provider across the UK, Western Europe, Scandinavia and Israel: Kreos has completed nearly 450 transactions and committed €1.8 billion in 14 different countries. Kreos has aproven track record of adding value to portfolio companies and helping them to grow with additional capital and flexibility throughout their business cycle whilst working closely with both the portfolio company management team and their equity sponsors.The Kreos global team has extensive debt financing, management and equity investing experience, covering the pan-European market from its locations in London, Tel Aviv and Stockholm.Kreos is a value added partner, able to offer additional capital and more flexibility with lower equity dilution. Kreos's international team has extensive entrepreneurial, debt financing and equity investing experience, covering all local European markets from its locations in London, Tel Aviv and Stockholm.

Investment focus

Biotechnology, Health Care, Software
Debt Financing, Series B, Post-IPO Debt
United Kingdom, Germany, United States

Portfolio highlights

Abivax — Abivax recently presented impressive 9-month interim extension data from studies of ABX464 in ulcerative colitis during an oral presentation at DDW 2019, demonstrating a continued duration of beneficial effect in patients after 11-months of treatment. View the conference presentation, here:
BiolineRx — BioLineRx is building a best-in-class pipeline designed to deliver meaningful therapeutic benefit to patients with certain cancers and rare diseases.
Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

HBM-MedFocus

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B
Ireland, United States

Portfolio highlights

Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Viseon — Viseon is a privately held medical device company committed to developing proprietary technology for use in Minimally Invasive Spine Surgery (MISS) procedures. Viseon has progressed rapidly over the past 6-months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive spine surgeryprocedures. In addition to rapid product development of its initial products, Viseon has assembled a world-class Scientific Advisory Board of leading MISS physicians, amassed 13 patents to solidify its intellectual property platform, and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon.Viseon was founded in early 2017 as a spin-out from Rebound Therapeutics Corporation.

Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem.Since our inception in 2013, they have raised £275 million to invest indisruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United Kingdom, United States, Ireland

Portfolio highlights

Riverlane — Riverlane's mission is to make quantum computing useful far sooner than previously imaginable, starting an era of human progress as significant as the industrial and digital revolutions.
T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is

Ali Partovi is the CEO and Founder of Neo. He previously worked at Dropbox as an Advisor. Ali Partovi attended Harvard University.

Investment focus

Software, Artificial Intelligence, E-Commerce
Seed, Series A, Pre-Seed
United States, Spain, Israel

Portfolio highlights

Expedock — Delivering Powerful Data Infrastructure for the Global Supply Chain. Experience AI technology that streamlines all logistics workflows with Expedock.
Ohana — Ohana is a company that allows users to find short-term housing and roommates.
Skiff — Everything on Skiff is end-to-end encrypted. Your most sensitive data is private, decentralized, and truly owned by you.

Cultivian Sandbox is a venture capital firm focused on building next-generation disruptive agriculture and food technology companies capable of generating superior returns. As early investors and active board members, we employ a hands-on approach to building companies and are often directly involved in setting company strategy, recruiting keyexecutives, and raising additional capital. Much more than simply a financial resource, we are capable of delivering tremendous value though active collaboration with our strategic partners and network, which are unparalleled in the agriculture and food industries.As both experienced operating managers and venture investors we add value to portfolio companies both through our highly skilled team and extensive industry network. Our investment team combines the domain expertise and investment experience from Cultivian Ventures and Sandbox Industries. Our expertise in sourcing, evaluating, closing, managing and ultimately exiting successful equity investments positions us not only to build stronger businesses, but reshape industries.

Investment focus

Science/Engineering, Agriculture/Farming, Biotechnology
Series A, Series B, Seed
United States, Canada, Germany

Portfolio highlights

Nuritas — Nuritas is revolutionising the discovery of novel, natural and scientifically proven active ingredients that can manage and improve human health. The company’s disruptive computational approach to discovery uses artificial intelligence and genomics to, for the first time ever, rapidly and efficiently predict and then provide access to the mosthealth-benefiting components hidden within food, called bioactive peptides.
Full Harvest — Waste less, profit more. Source imperfect and surplus fruits and vegetables up to 10-30% off.
Leaf Agriculture — Leaf is a data network that connects apps and services to farm data from equipment, sensor, and software platforms.Leaf’s API allows developers to easily validate grower consent, access high-quality agriculture data, and scale their products. With Leaf, developers are building a food system that makes it healthier, increases farmers’ profits,benefits the environment, and is accessible to everyone.

Medicxi is a life sciences-focused investment firm, originally created at Index Ventures, a leading international venture capital firm with offices in London, San Francisco, Geneva, and St. Helier (Jersey).Francesco De Rubertis joined Index at the end of 1997 to launch the firm's life sciences practice and was joined in the following yearsby three partners: Kevin Johnson, Michèle Ollier and David Grainger. Over the years, Index raised a total of twelve funds, managed with separate life sciences and technology investment teams.In 2012, Index launched sector-specific venture funds for the first time, raising separately Index Ventures VI (technology focus) and Index Life VI (life sciences focus). Global Pharma GlaxoSmithKline (NYSE: GSK) and affiliates of Johnson & Johnson (Janssen; NYSE: JNJ) both partnered with Index by investing in Index Life VI. This was a key step in the path towards the founding of Medicxi as an independent venture firm. (read here)Medicxi started its operations in February 2016, with offices in London, Geneva and St Helier (Jersey). Giuseppe Zocco, co-founder of Index Ventures, joined Medicxi shortly thereafter to help build the firm’s late-stage platform and lead the launch of its first Medicxi Growth fund, MG1. (read here)Currently, the firm is actively investing its 2 most recent funds, Medicxi Ventures 1 (focus on early-stage companies) and Medicxi Growth 1 (focus on later stage companies), in addition to managing the entire portfolio of all prior Index life sciences investments.The firm is led by its five co-founders and Partners: Francesco, Kevin, Michèle, David and Giuseppe. Over the years, the five of them have collectively been involved in starting over seventy companies in several countries.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, The Netherlands

Portfolio highlights

D3 Bio — D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path.
ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
Alys Pharmaceuticals — Alys Pharmaceuticals engages in immuno-dermatology services. The company is reshaping the treatment landscape through advanced scientific innovations and a strong research and development-focused multi-platform pipeline. Alys emerged as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi.

Apicap offers investment and co-investment solutions for managers, wealthy private clients and institutional investors.

Investment focus

Software, Information Technology, Mobile
Funding Round, Series A, Series B
France, United States, Turkey

Portfolio highlights

Crowdaa — Crowdaa is a mobile-only music store where producers decide how to distribute and monetise their content.
Feelbat — FEELBAT offers technical solutions for remote crack monitoring, covering installation and data analysis to assist in wall monitoring.
Karma Koma — Karma Koma is specializes in retail and French and international distribution with multi-brand resellers.

The Foundry, LLC is the premier medical device company incubator. We work with inventors to rapidly transform their concepts into companies by providing an incomparable combination of leadership, an experienced, multi-disciplinary team, a state-of-the-art facility and an extensive funding network. The Foundry Team is comprised of veteran medicaldevice entrepreneurs and investors with real world experienceâ€”and successâ€”in developing world class medical device companies.

Investment focus

Health Care, Biotechnology, Science/Engineering
Series A
Ireland

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Founded in 1997, Earlybird invests in all development and growth phases of technology companies. Among the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources but also strategic support plus access to an international network and capital markets. With EUR 2 billion under management,eight IPOs and 30 trade sales, Earlybird is one of the most established and active venture capital firms in Europe.

Investment focus

Software, Information Technology, Health Care
Series A, Seed, Series B
Germany, United States, United Kingdom

Portfolio highlights

Proofs — The go-to-market for software. AI Agents building proof-of-concept apps and integrations on top of APIs
M^0 Labs — M^0 is money middleware for the digital age. It is a decentralized, on-chain protocol, as well as a corresponding set of off-chain standards and APIs, that allows holders of high-quality eligible collateral to participate in the issuance of a fungible cryptodollar. With M^0, any number of institutions around the world can tap on turnkey middlewareto become their own cryptodollar issuer, upgrading their money tech stack to the digital age.
Zeta Labs — Revolutionize daily tasks with our AI assistant. Not just a chatbot - it chats, understands, and performs. Free yourself to focus on meaningful things.

Elkstone is an investment firm, focusing on entrepreneurs, senior executives, institutional LPs, the venture community, and the Irish diaspora.The objective of the organization is to boost the economic value and overall well-being of the island of Ireland by expanding a network, facilitating deserving investments, and delivering excellentinvestment performance.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United Kingdom, United States

Portfolio highlights

Numra — Numra is an artificial intelligence automation for financial operations.
Jamango — Create and play for free in Jamango! Play with our block-based tools to make anything or explore a library of games and worlds instantly. No downloads.
Wellola — Wellola connects clinics & their own clients, anywhere, anytime. It is designed for the forward-thinking healthcare professional. Our cloud-based platform offers secure video-consultation software combined with simple payment/practice management facilities.

EarlyBird is a postal snacking service that delivers healthy snacks to its users’ doorstep. It provides its users with TasteBox, 5 healthy snacks and 2 unique teas, to help them through the working week. Its TasteBox also contains music and art from up and coming artists. EarlyBird was launched in 2014 and is based in London, England.

Investment focus

Financial Services, FinTech, Health Care
Seed, Series A, Pre-Seed
Germany, Ireland, Romania

Portfolio highlights

Sikoia — Streamline your decision-making with centralized customer data, comprehensive case management, and automated risk evaluation without complicated integrations.
Noscendo — Noscendo operates as a diagnostics company dedicated to the identification and assessment of bloodstream-associated pathogens and other infections.
Goodlegal — Goodlegal is the One-Stop-Shop for all your Legal needs. Get an out-of-the-box Legal Infrastructure Platform to handle all your problems.

Carragh Holdings

Investment focus

Biotechnology, Bioinformatics
Series A
Ireland

Portfolio highlights

Kastus Technologies — Kastus is embedded into glass during manufacturing. Creating the world's first surface that constantly cleans itself of over 99% of germs and viruses, including Covid 19. It works 24/7, for the lifetime of the glass.

Medtech Syndicate Nominee

Investment focus

Medical, Health Care, Medical Device
Seed, Series A, Funding Round
Ireland

Portfolio highlights

Kite Medical — Kite medical has developed a novel device for detecting Kidney Reflux in children with Urinary Tract Infections. The non-invasive diagnostic solution for kidney reflux removes the need for complicated procedures and a hospital visit. Kidney reflux is the most common urological disorder in childhood, affecting up to three per cent of young children.It is most prevalent from six months to five years of age. The condition may resolve as the child gets older, but left undiagnosed and untreated it can lead to permanent kidney damage and ultimately to kidney failure.
Signum Surgical — Founded in 2014 by Eoin Bambury and Moshe Zilversmit, Signum Surgical is a medtech platform striving to develop technology that could cure perianal fistula. Bambury and Zilversmit, who met on the BioInnovate Ireland programme at NUI Galway, recognised a lack of innovation surrounding the treatment of perianal fistulas (small tunnels that developbetween the end of the bowel and the skin near the anus). The device developed by Signum Surgical is implanted post-surgery to prevent reinfection and to allow a faster healing process.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

We are dedicated to helping investors reach their investment goals. Get in touch with our team to explore abrdn's investment options.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
United States, Switzerland, France

Portfolio highlights

Invetx — Our team of R&D leaders from human biotech and animal health is building the premier biotechnology platform for protein-based therapeutics in animal health.
Oculis — The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
Amolyt Pharma — We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.

KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally.With each of our 300+ client partners, we have worked closely to personalize and rapidly accelerate their drug developmentprograms. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs.We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), San Diego (CA), and Leuven, Belgium.

Investment focus

Biotechnology, Life Science, Medical
Seed, Series A, Series D
United States, Ireland

Portfolio highlights

Absci — A better, faster path to new medicines. We translate ideas into drugs with an AI-powered approach to biologic drug discovery and cell line development.
GlycoSeLect — GlycoSeLect Ltd specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs).
ReForm Biologics — ReForm Biologics is an engineering superior biotherapeutic formulation for fragile patients. Its proprietary technology provides patented, FDA-friendly excipients for a wide range of therapeutic biologics. Using its platforms, drug companies can make life-saving medicines easier to administer, less immunogenic, more stable, and more efficient toproduce. It was founded in 2014 and is based in Woburn, Massachusetts.

Third Swedish National Pension Fund employs different investment strategies in the interest of spreading risk and protecting pensions for current and future pensioners. The firm was founded in 2001 and is headquartered in Stockholm, Sweden.

Investment focus

Biotechnology, Battery, CleanTech
Funding Round, Post-IPO Equity
Sweden, Denmark, Ireland

Portfolio highlights

Saniona — Improving the lives of rare disease patients around the world through scientific innovation.
Northvolt — Northvolt develops sustainable lithium-ion batteries in conjunction with R&D, industrialization, and recycling to support clean energy. It provides electrification and renewable energy storage designed for lithium-ion battery plant to produce batteries for electric vehicles. Northvolt's product is an environment-friendly batterymanufactured with minimal carbon footprint and with recycling technology without compromising with important eco-systems, enabling the auto industry to replace fossil fuels with electricity in an efficient manner. The company aims to establish a supply of sustainable battery cells and systems.In 2016, Paolo Cerruti and Peter Carlsson headquartered the company in Stockholm, Stockholms Lan.
Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.

Investors by industry

FinTech

Consumer

Gaming

Media (entertainment)

EdTech

Artificial intelligence